SAT538 Thyrotoxicosis in the Setting of Metastatic Poorly Differentiated Thyroid Carcinoma, a Marker of Disease Progression?

Disclosure: B.L. Chang: None. M.A. Fernandez: None. K.M. Shikuma Lee: None. Background: Thyrotoxicosis is a rare manifestation of thyroid cancer, and poorly differentiated thyroid carcinoma (PDTC) causing thyrotoxicosis has even more rarely been reported. Here, we report a case of PDTC with thyrotox...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the Endocrine Society 2023-10, Vol.7 (Supplement_1)
Main Authors: Chang, Bolin L, Fernandez, Mayumi A, Shikuma Lee, Kelsey M
Format: Article
Language:English
Subjects:
Thyroid
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue Supplement_1
container_start_page
container_title Journal of the Endocrine Society
container_volume 7
creator Chang, Bolin L
Fernandez, Mayumi A
Shikuma Lee, Kelsey M
description Disclosure: B.L. Chang: None. M.A. Fernandez: None. K.M. Shikuma Lee: None. Background: Thyrotoxicosis is a rare manifestation of thyroid cancer, and poorly differentiated thyroid carcinoma (PDTC) causing thyrotoxicosis has even more rarely been reported. Here, we report a case of PDTC with thyrotoxicosis developing in a previously euthyroid individual with longstanding untreated follicular neoplasm. Clinical Case: A 79-year-old veteran presented to routine endocrine follow up with new symptoms of thyrotoxicosis. Although previously euthyroid, the evaluation revealed new findings of low serum thyrotropin (TSH) (
doi_str_mv 10.1210/jendso/bvad114.2009
format article
fullrecord <record><control><sourceid>pubmedcentral_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10554434</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_10554434</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1459-c6edbb6b04cc7611866cf891d0eb2d6f4c15dd4be6a1b2487e16c567ec1a43ff3</originalsourceid><addsrcrecordid>eNpVkd1qAjEQhZfSQsX6BL3JA1TN7Gaz7pWI9g-UCtrrkE0mGqsbSVKp0IevslLaqzkwnI8DX5LcA-1BCrS_wVoH168OUgOwXkppeZW0UlakXSiL9PpPvk06IWwopVBmrGSslXwvRss8G5Dl-uhddF9WuWADsTWJayQLjNHWK-IMmWGUIcpoFZk757dHMrHGoMc6WhlRNwSryVh6ZWu3kw9Ekpn0H-jP_YkNKAOSuXcrjyFYVw_vkhsjtwE7l9tO3p8el-OX7vTt-XU8mnYVsLzsKo66qnhFmVIFBxhwrsygBE2xSjU3TEGuNauQS6hSNigQuMp5gQoky4zJ2smw4e4_qx1qddrs5Vbsvd1JfxROWvH_U9u1WLmDAJrnjGXsRMgagvIuBI_mtwxUnC2IxoK4WBBnC9kPJDiBdw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>SAT538 Thyrotoxicosis in the Setting of Metastatic Poorly Differentiated Thyroid Carcinoma, a Marker of Disease Progression?</title><source>PubMed Central Free</source><source>Oxford Open Access Journals</source><creator>Chang, Bolin L ; Fernandez, Mayumi A ; Shikuma Lee, Kelsey M</creator><creatorcontrib>Chang, Bolin L ; Fernandez, Mayumi A ; Shikuma Lee, Kelsey M</creatorcontrib><description>Disclosure: B.L. Chang: None. M.A. Fernandez: None. K.M. Shikuma Lee: None. Background: Thyrotoxicosis is a rare manifestation of thyroid cancer, and poorly differentiated thyroid carcinoma (PDTC) causing thyrotoxicosis has even more rarely been reported. Here, we report a case of PDTC with thyrotoxicosis developing in a previously euthyroid individual with longstanding untreated follicular neoplasm. Clinical Case: A 79-year-old veteran presented to routine endocrine follow up with new symptoms of thyrotoxicosis. Although previously euthyroid, the evaluation revealed new findings of low serum thyrotropin (TSH) (&lt;0.01 uIU/mL, n=0.34 – 5.60 uIU/mL), elevated free thyroxine (FT4) (2.6 ng/dL, n=0.58 – 1.64 ng/dL), and high total T3 (TT3) levels (223 ng/dL, n=76 – 181 ng/dL). Thyroid stimulating immunoglobulin antibodies (TSI) were positive (214, n&lt;140). Patient has a nine-year history of a fine needle aspiration (FNA) of a large right-sided thyroid nodule with cytology suspicious for follicular neoplasm but declined surgical removal. Thyroid uptake and scan showed heterogeneous uptake throughout the right lobe with a relative photopenic region centrally and spots of more increased activity in areas within the right lobe. The left thyroid lobe showed uniformly low uptake. PET-CT evaluation confirmed spotty FDG-avid areas within the right thyroid mass but did not show other areas of hyperactivity. Methimazole was started with clinical and biochemical improvement. Patient underwent total thyroidectomy, and histopathologic examination showed PDTC with extensive angioinvasion involving the majority of the right thyroid lobe with the left lobe containing a mix of benign thyroid tissue and PDTC fragments. Areas of hyperintensity on the uptake scan correlated to pathological PDTC locations within the right lobe. Within three weeks of thyroidectomy, patient developed recurrent hyperthyroidism. Laboratory studies showed low TSH (0.04 uIU/mL) and elevated FT4 (2 ng/dL). In contrast to pre-operative studies, repeat TSI was below the reference range. Levothyroxine (LT4) was held in anticipation of radioactive iodine therapy, but four weeks later the TSH remained suppressed. 131I was administered which showed accumulation within small thyroid remnants and a single left level three 131I-avid lymph node without other metastases. Following 131I treatment, patient returned to a euthyroid state on standard LT4. Conclusion: Hyperthyroidism has rarely been associated with PDTC, although previous reports have linked more aggressive, multifocal, and locally invasive thyroid cancers to concurrent Graves’ disease or productive bulky metastatic disease. Even without bulky metastatic disease, clinicians should be aware that hyperproductivity may indicate development of autoimmune thyrotoxicosis within PDTC. Presentation Date: Saturday, June 17, 2023</description><identifier>ISSN: 2472-1972</identifier><identifier>EISSN: 2472-1972</identifier><identifier>DOI: 10.1210/jendso/bvad114.2009</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Thyroid</subject><ispartof>Journal of the Endocrine Society, 2023-10, Vol.7 (Supplement_1)</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554434/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554434/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Chang, Bolin L</creatorcontrib><creatorcontrib>Fernandez, Mayumi A</creatorcontrib><creatorcontrib>Shikuma Lee, Kelsey M</creatorcontrib><title>SAT538 Thyrotoxicosis in the Setting of Metastatic Poorly Differentiated Thyroid Carcinoma, a Marker of Disease Progression?</title><title>Journal of the Endocrine Society</title><description>Disclosure: B.L. Chang: None. M.A. Fernandez: None. K.M. Shikuma Lee: None. Background: Thyrotoxicosis is a rare manifestation of thyroid cancer, and poorly differentiated thyroid carcinoma (PDTC) causing thyrotoxicosis has even more rarely been reported. Here, we report a case of PDTC with thyrotoxicosis developing in a previously euthyroid individual with longstanding untreated follicular neoplasm. Clinical Case: A 79-year-old veteran presented to routine endocrine follow up with new symptoms of thyrotoxicosis. Although previously euthyroid, the evaluation revealed new findings of low serum thyrotropin (TSH) (&lt;0.01 uIU/mL, n=0.34 – 5.60 uIU/mL), elevated free thyroxine (FT4) (2.6 ng/dL, n=0.58 – 1.64 ng/dL), and high total T3 (TT3) levels (223 ng/dL, n=76 – 181 ng/dL). Thyroid stimulating immunoglobulin antibodies (TSI) were positive (214, n&lt;140). Patient has a nine-year history of a fine needle aspiration (FNA) of a large right-sided thyroid nodule with cytology suspicious for follicular neoplasm but declined surgical removal. Thyroid uptake and scan showed heterogeneous uptake throughout the right lobe with a relative photopenic region centrally and spots of more increased activity in areas within the right lobe. The left thyroid lobe showed uniformly low uptake. PET-CT evaluation confirmed spotty FDG-avid areas within the right thyroid mass but did not show other areas of hyperactivity. Methimazole was started with clinical and biochemical improvement. Patient underwent total thyroidectomy, and histopathologic examination showed PDTC with extensive angioinvasion involving the majority of the right thyroid lobe with the left lobe containing a mix of benign thyroid tissue and PDTC fragments. Areas of hyperintensity on the uptake scan correlated to pathological PDTC locations within the right lobe. Within three weeks of thyroidectomy, patient developed recurrent hyperthyroidism. Laboratory studies showed low TSH (0.04 uIU/mL) and elevated FT4 (2 ng/dL). In contrast to pre-operative studies, repeat TSI was below the reference range. Levothyroxine (LT4) was held in anticipation of radioactive iodine therapy, but four weeks later the TSH remained suppressed. 131I was administered which showed accumulation within small thyroid remnants and a single left level three 131I-avid lymph node without other metastases. Following 131I treatment, patient returned to a euthyroid state on standard LT4. Conclusion: Hyperthyroidism has rarely been associated with PDTC, although previous reports have linked more aggressive, multifocal, and locally invasive thyroid cancers to concurrent Graves’ disease or productive bulky metastatic disease. Even without bulky metastatic disease, clinicians should be aware that hyperproductivity may indicate development of autoimmune thyrotoxicosis within PDTC. Presentation Date: Saturday, June 17, 2023</description><subject>Thyroid</subject><issn>2472-1972</issn><issn>2472-1972</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVkd1qAjEQhZfSQsX6BL3JA1TN7Gaz7pWI9g-UCtrrkE0mGqsbSVKp0IevslLaqzkwnI8DX5LcA-1BCrS_wVoH168OUgOwXkppeZW0UlakXSiL9PpPvk06IWwopVBmrGSslXwvRss8G5Dl-uhddF9WuWADsTWJayQLjNHWK-IMmWGUIcpoFZk757dHMrHGoMc6WhlRNwSryVh6ZWu3kw9Ekpn0H-jP_YkNKAOSuXcrjyFYVw_vkhsjtwE7l9tO3p8el-OX7vTt-XU8mnYVsLzsKo66qnhFmVIFBxhwrsygBE2xSjU3TEGuNauQS6hSNigQuMp5gQoky4zJ2smw4e4_qx1qddrs5Vbsvd1JfxROWvH_U9u1WLmDAJrnjGXsRMgagvIuBI_mtwxUnC2IxoK4WBBnC9kPJDiBdw</recordid><startdate>20231005</startdate><enddate>20231005</enddate><creator>Chang, Bolin L</creator><creator>Fernandez, Mayumi A</creator><creator>Shikuma Lee, Kelsey M</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20231005</creationdate><title>SAT538 Thyrotoxicosis in the Setting of Metastatic Poorly Differentiated Thyroid Carcinoma, a Marker of Disease Progression?</title><author>Chang, Bolin L ; Fernandez, Mayumi A ; Shikuma Lee, Kelsey M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1459-c6edbb6b04cc7611866cf891d0eb2d6f4c15dd4be6a1b2487e16c567ec1a43ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Thyroid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang, Bolin L</creatorcontrib><creatorcontrib>Fernandez, Mayumi A</creatorcontrib><creatorcontrib>Shikuma Lee, Kelsey M</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the Endocrine Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang, Bolin L</au><au>Fernandez, Mayumi A</au><au>Shikuma Lee, Kelsey M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SAT538 Thyrotoxicosis in the Setting of Metastatic Poorly Differentiated Thyroid Carcinoma, a Marker of Disease Progression?</atitle><jtitle>Journal of the Endocrine Society</jtitle><date>2023-10-05</date><risdate>2023</risdate><volume>7</volume><issue>Supplement_1</issue><issn>2472-1972</issn><eissn>2472-1972</eissn><abstract>Disclosure: B.L. Chang: None. M.A. Fernandez: None. K.M. Shikuma Lee: None. Background: Thyrotoxicosis is a rare manifestation of thyroid cancer, and poorly differentiated thyroid carcinoma (PDTC) causing thyrotoxicosis has even more rarely been reported. Here, we report a case of PDTC with thyrotoxicosis developing in a previously euthyroid individual with longstanding untreated follicular neoplasm. Clinical Case: A 79-year-old veteran presented to routine endocrine follow up with new symptoms of thyrotoxicosis. Although previously euthyroid, the evaluation revealed new findings of low serum thyrotropin (TSH) (&lt;0.01 uIU/mL, n=0.34 – 5.60 uIU/mL), elevated free thyroxine (FT4) (2.6 ng/dL, n=0.58 – 1.64 ng/dL), and high total T3 (TT3) levels (223 ng/dL, n=76 – 181 ng/dL). Thyroid stimulating immunoglobulin antibodies (TSI) were positive (214, n&lt;140). Patient has a nine-year history of a fine needle aspiration (FNA) of a large right-sided thyroid nodule with cytology suspicious for follicular neoplasm but declined surgical removal. Thyroid uptake and scan showed heterogeneous uptake throughout the right lobe with a relative photopenic region centrally and spots of more increased activity in areas within the right lobe. The left thyroid lobe showed uniformly low uptake. PET-CT evaluation confirmed spotty FDG-avid areas within the right thyroid mass but did not show other areas of hyperactivity. Methimazole was started with clinical and biochemical improvement. Patient underwent total thyroidectomy, and histopathologic examination showed PDTC with extensive angioinvasion involving the majority of the right thyroid lobe with the left lobe containing a mix of benign thyroid tissue and PDTC fragments. Areas of hyperintensity on the uptake scan correlated to pathological PDTC locations within the right lobe. Within three weeks of thyroidectomy, patient developed recurrent hyperthyroidism. Laboratory studies showed low TSH (0.04 uIU/mL) and elevated FT4 (2 ng/dL). In contrast to pre-operative studies, repeat TSI was below the reference range. Levothyroxine (LT4) was held in anticipation of radioactive iodine therapy, but four weeks later the TSH remained suppressed. 131I was administered which showed accumulation within small thyroid remnants and a single left level three 131I-avid lymph node without other metastases. Following 131I treatment, patient returned to a euthyroid state on standard LT4. Conclusion: Hyperthyroidism has rarely been associated with PDTC, although previous reports have linked more aggressive, multifocal, and locally invasive thyroid cancers to concurrent Graves’ disease or productive bulky metastatic disease. Even without bulky metastatic disease, clinicians should be aware that hyperproductivity may indicate development of autoimmune thyrotoxicosis within PDTC. Presentation Date: Saturday, June 17, 2023</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1210/jendso/bvad114.2009</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2472-1972
ispartof Journal of the Endocrine Society, 2023-10, Vol.7 (Supplement_1)
issn 2472-1972
2472-1972
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10554434
source PubMed Central Free; Oxford Open Access Journals
subjects Thyroid
title SAT538 Thyrotoxicosis in the Setting of Metastatic Poorly Differentiated Thyroid Carcinoma, a Marker of Disease Progression?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T06%3A08%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SAT538%20Thyrotoxicosis%20in%20the%20Setting%20of%20Metastatic%20Poorly%20Differentiated%20Thyroid%20Carcinoma,%20a%20Marker%20of%20Disease%20Progression?&rft.jtitle=Journal%20of%20the%20Endocrine%20Society&rft.au=Chang,%20Bolin%20L&rft.date=2023-10-05&rft.volume=7&rft.issue=Supplement_1&rft.issn=2472-1972&rft.eissn=2472-1972&rft_id=info:doi/10.1210/jendso/bvad114.2009&rft_dat=%3Cpubmedcentral_cross%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_10554434%3C/pubmedcentral_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1459-c6edbb6b04cc7611866cf891d0eb2d6f4c15dd4be6a1b2487e16c567ec1a43ff3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true